1 / 23

Dr. Pharm. Maija Dambrova, Manager

Dr. Pharm. Maija Dambrova, Manager. Strengthening the research and innovative capacities of the Latvian Institute of Organic Synthesis, the leading Baltic regional centre for drug discovery. Project acronym: InnovaBalt Type of funding scheme: Coordination and support actions

hallie
Télécharger la présentation

Dr. Pharm. Maija Dambrova, Manager

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Dr. Pharm. Maija Dambrova, Manager Strengthening the research and innovative capacities of the Latvian Institute of Organic Synthesis, the leading Baltic regional centre for drug discovery

  2. Project acronym: InnovaBalt Type of funding scheme: Coordination and support actions Work programme topics addressed: REGPOT-2012-2013-1 Total cost:5.2 million euro Contribution of EC: 4.7 million euro

  3. Strategic objective of the project to strengthenthe multidisciplinary research capacities, management of intellectual property as well as human resources in the innovative drug discoveryat Latvian Institute of Organic Synthesis

  4. Short term objectives of the project: Establishment and strengthening the long-lasting scientific collaboration and strategic partnership between LIOS and outstanding research institutions in ERA Increasing the innovation and improving of management of intellectual property through collaboration and attraction of external professionals Upgrading the research infrastructure at LIOS to promote the capacity for the high level research on innovative drug development; Increasing the visibility of LIOS in ERA Ensuring the synergy between research on innovative drug development and end-users (SMEs, industry, clinics, patients’ organizations) Reinforcing the strategic development of LIOS to improve the response to socio-economic needs of Baltic region in health area

  5. Strategic partnering organizations

  6. Scientific Steering Committee Representative from Latvian Ministry of Education and Science Professor Raimonds Valters from Latvian Academy of Sciences Dr. Andis Slaitas, managing director of Syntagon Baltic Professor Ari Koskinen from Aalto University, Finland Professor Daumantas Matulis from the Institute of Biotechnology, Lithuania Professor Ad IJzerman from Leiden University, the Netherlands Professor Claudiu Supuran from University of Florence, Italy Dr. Eriks Kupce Bruker Biospin, UK Professor Edvards Liepinsh from LIOS Professor Gunars Duburs from LIOS

  7. Action plan of InnovaBalt project Cardio­ vascular diseases Infectious diseases Cancer Diabetesand obesity Neuro­ degenerative diseases Multidisciplinarity: chemical synthesis, molecular modelling, pharmacological activities,targeted drug delivery forms, green chemistry Advanced IP management and protection, innovation capacity building Training of young and experienced researchers Collaboration with stakeholders (policy makers, SMEs, industry, universities, hospitals, patient organizations, society) Integration in European research area to contribute in the solution of current socio-economical needs in health area

  8. Organizational structure EC WP8 Management Project manager Maija Dambrova Steering Committee for Research Strategy Project coordinator Ivars Kalvins WP1 A.Sobolevs WP2 L.Ignatovich WP3 O.Pugovics WP4 P.Trapencieris WP5 D.Tirzite WP6 I.Kalvins WP7 G.Veinbergs EU Partners

  9. Work packages WP1. Exchange of experience and know-how (via international two-way secondmentsof experienced and young researchers of LIOS with researchers from excellent and complementary European research centres) WP2. Strengthening of the research potential of human resources WP3. Renewal of research equipment WP4. Organization of seminars and conferences WP5. Improving the management of Intellectual Property and enhancement of innovation potential WP6. Dissemination and promotional activities WP7. External Assessment of LIOS WP8. Management

  10. WP1 Exchange of experience and know-how WP1 leader: Dr. chem. ArkadijSobolev Taskleaders: Dr.chem. Kristaps Jaudzems, Dr. pharm. Edgars Liepiņš, Dr. chem. Aiva Plotniece, Dr. pharm. Maija Dambrova Exchange of know-how and experience via international two-waysecondments of experienced scientists and young scientists between the LIOS and leading scientific institutions in the ERA • to explore the opportunities for building of lasting networks • to gain the access to complementary equipment, data observations and ideas.

  11. WP2 Strengthening of the research potential of human resources WP2 leader Dr.hab,chem. Lubova Ignatovich Objectives: • To increase the LIOS research capacity and experience in new directions of drug discovery by recruitment of experienced researchers • To increase the international-level transfer process of accumulated knowledge and technologies through the reintegration of experienced researchers from abroad • To increase the research potential of existing laboratories by recruitment of post-doctoral researchers The project foresees the recruitment of 8 experienced researchers and 6 post-doctoral researchers

  12. WP3 Renewal of research equipment WP3 leader: Dr.chem. OsvaldsPugovičs Taskleaders: Dr.chem. Kristaps Jaudzems, Dr. pharm. Edgars Liepiņš, Dr. chem. Aiva Plotniece Objectives: 1. Acquisition of modern equipment and tools necessary for innovative drug development 2. Upgrading the research equipment

  13. WP 4Organization of conferences, seminars, trainings WP leader Dr. Chem. Pēteris Trapencieris Taskleaders: Dr. Aiva Plotniece, Dr. Maija Dambrova, Dr. Arkādijs Soboļevs, Dr. Kristaps Jaudzems, Dr. RaivisŽalubovskis, Dr. Osvalds Pugovičs, Ieva Jaunzeme Objectives: • To facilitate the knowledge transfer at the national, regional and international levels • To increase the visibility of LIOS by dissemination of the results of Latvian scientists in organic chemistry, medicinal chemistry of heterocycles, structure-activity relationships, experimental chemotherapy and pharmacology to the international scientific community. • To strengthen the long-lasting scientific collaboration between LIOS and partnering organisations in ERA.

  14. WP4 Events Workshop “Ready for Horizon 2020” (Winter 2013/2014) Seminar “Advanced antiinfective drug design” (Spring 2014) Workshop on publication writing for scientific journals and on popular science(Autumn 2013) Seminar „Biophysical methods in drug discovery” (Spring 2014) Seminar „Protein production techniques” (Spring 2014) BOS-2014 pre-conference roundtable (June 2014) Workshop „Competitive proposal preparation for Horizon 2020” (Autumn 2014) GustavsVanags memorial conference ( Autumn 2014) Conference “BaltDrug” (May 2015) Conference “Paul Walden 9th Symposium” ( Autumn 2015) BOS-2016 pre-conference roundtable (June 2016) BOS-2016 conference (June 2016) Participation of LIOS researchers in transnational events

  15. WP5Improving the management of Intellectual Property and enhancement of innovation potential WP leader Prof.I.Kalvins The strategy of this WP is based on 3 principles: • development – by providing the strategic Intellectual Property development plan for the effective management of IPR and efficient technology transfer process • collaboration –with governmental institutions, research, academia, industry, technology transfer centres and other stakeholders on the issues of innovation and IPR; by networking with partnering organizations • awareness – by training and education of experienced and early stage researchers as well as entrepreneurs on the IPR and technology transfer issues

  16. WP6 Dissemination and promotional activities WP leader Dr. Biol.DaceTirzīte Team: EdīteMētere, Dr. AntonsĻebedevs, Dr. AigarsJirgensons, Dr. RaivisŽalubovskis, Dr. RonaldsZemribo Objectives: • Promotion of InnovaBalt within the scientific community of Europe • Dissemination of information on advanced innovative medicine development to the industry sector and other stakeholders • Providing the information for society on topicalities in innovative drug development and results of InnovaBalt

  17. WP8Assessment of research and innovative potential of LIOS WP leader Dr.chem Grigorijs Veinberg The evaluation of LIOS’ overall research quality and capability by high-level independent experts, nominated by European Commission. The evaluation will give essential contribution in the definition of the further Strategic plan to strengthen LIOS research and innovation capacities essential for the regional economical and social development as well as promoting the integration of LIOS in the ERA activities.

  18. WP7Management of project WP leader Dr.pharm Maija Dambrova Management board: financial director of LIOS Dace Karkle Dr. EdgarsSuna, Dr. A. Jirgensons, Dr. Edgars Liepinsh Objectives: • Setting up the appropriate monitoring, coordination and communication procedures inorder to ensure that project is implemented in a timely and cost effective manner inaccordance with applicable EC guidelines and national legislation rules • Ensuring that EC financial and administrative procedures are respected and reports andcost statements are provided in time

  19. Overall organization WP8 Project Management T8.1 Network management structure procedures T8.2 Administrative and financial management T8.3 Project technical co-ordination and quality policies WP1 Exchange of experience and know-how WP2 Reinforcing human potential WP3 Renewal of research equipment WP4 Organization of seminars and conferences WP5 Improving the management of IP and enhancement of innovation potential T3.1 Ccomputer cluster T1.1 Staff exchange planning T2.1 Recruitment of experienced researchers T4.1 Organization of conferences T5.1 Recruitment of experienced IP manager T3.2 Crystallization robot T4.2 Participation in conferences T1.2 Implementation of outgoing visits T2.2 post-doctoral researchers T3.3 Zetasizer Nano T5.2 Development of IP policy T1.3 Implementation of incoming visits T3.4New imaging Technologies T5.3 Staff exchange and training WP6 Dissemination and promotional activities T6.1 Elaboration of dissemination strategy T6.2 Exploitation of InnovaBalt results T6.3 Providing Information to industry and SMEs WP7 Assessment of LIOS T7.1 Kick-off meeting of the Experts group T7.1 Communication and interaction with Expert group T7.3 Evaluation report and recommendations for Strategic Plan T7.4 Workshop on evaluation results InnovaBalt the leading centre for drug discovery inBaltic region

  20. The main strategic impacts • Contribution to the research, technology and innovation capacity building in Baltic region: • by strengthening human capacity • improvement of technology environment and • management of intellectual property • promotion of collaboration between research centres • facilitating of cooperation with industry. • Strong integration in ERA: through long-lasting partnership with selected European research centres • Improved participation in FP Horizon 2020 and other European research programmes’ activities: • increasingthe skills and awareness about the preparation of competitive proposals and • improving the management skills • networking with other research centres and industry • establishing new partnerships.

  21. Future expectations The implementation of InnovaBalt project will result in 1.5 times increase in number of SCI publications co-authored by LOSI personnel and 1.2 times increase in number of registered international patents Reinforced IPR culture is expected to facilitate the collaboration with business sector and improve the score of Latvia and Baltic region in the Global Innovatin index. LIOS will become the distinguished centre of research and innovation in the Baltic region in the field of medicinal chemistry and pharmacology and will provide the contribution in the solving of socio-economic needs of European society.

  22. Thank you for attention!Paldies par uzmanību!

More Related